Developer docs
API playgroundTry for free, no card

Search company profiles

Eikon Therapeutics

Full company profile

uuid00004xi

Namestring
Eikon Therapeutics
Legal namestring
Eikon Therapeutics, Inc.
Websiteurl
eikontx.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that develops live-cell resolution microscopy and engineering tools for drug discovery. Founded in 2019 in Millbrae, California by Robert Tjian, Luke Lavis, Xavier Darzacq, and Nobel laureate Eric Betzig, the company completed an upsized initial public offering on Nasdaq (ticker: EIKN) on February 5, 2026, raising approximately $381 million in gross proceeds. Eikon applies its proprietary Single Molecule Tracking (SMT) platform — built on Nobel Prize-winning super-resolution microscopy and extended through the proprietary Oblique Line Scan (OLS) illumination technology — to visualize and measure the real-time movement of individual proteins in living cells at industrial scale, generating approximately one petabyte of imaging data per week.

The company's pipeline centers on clinical-stage oncology candidates, including EIK1001, a TLR7/8 dual agonist in Phase 2 development in first-line Stage 4 NSCLC and advanced melanoma in combination with pembrolizumab; EIK1003 and EIK1004, PARP1-selective inhibitors in Phase 1/2 development (EIK1004 is differentiated by CNS penetrance); EIK1005, a WRN helicase inhibitor that entered Phase 1/2 in February 2026 as the first program advanced from internal SMT discovery; and EIK1006, an androgen receptor antagonist in IND-enabling studies. The Eikon Systems business unit, established in 2024, extends SMT imaging instruments to external academic and industry researchers through the Eikon Technology Access Program.

Eikon is pre-revenue and operates a capital-intensive, clinical-development-driven business model with no approved products on market. Revenue mechanics currently consist of (1) capital deployment (over $1.1 billion raised privately plus $381M IPO proceeds) funding registration-enabling Phase 2/3 trials and Phase 1 programs across 28 countries on 5 continents, and (2) early-stage Eikon Systems instrument access. The company reported a FY2025 net loss of $333.6M and Q1 2026 net loss of $83.0M, with cash, cash equivalents, and marketable securities of $596.0 million as of March 31, 2026, expected to fund operations into the second half of 2027. Strategic collaboration with Merck & Co. covers pembrolizumab supply for EIK1001 trials, and Impact Therapeutics handles greater China clinical operations for EIK1003/EIK1004.

Short descriptiontext

Eikon Therapeutics is a clinical-stage biopharmaceutical company that uses proprietary live-cell Single Molecule Tracking microscopy — built on Nobel Prize-winning super-resolution optics — to discover and develop oncology drug candidates including TLR7/8 and PARP1 inhibitors, serving patients with advanced and treatment-resistant cancers.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMillbrae, United States
HQ citystring
Millbrae
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, single molecule imaging, live-cell microscopy, clinical-stage biopharmaceuticals, drug discovery platform
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Clinical-stage Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage biopharmaceutical
TypeLicensing Royalties
Description

Eikon is pre-revenue as of Q1 2026; net loss was $83.0 million in Q1 2026 and $333.6 million for full-year 2025, with no approved products on the market. Future revenue expected from commercialization of oncology drug candidates (EIK1001, EIK1003, EIK1004, EIK1005, EIK1006) once approved.

eikontx.com
2Eikon Systems / Technology Access Program
TypeProfessional Services
Description

Eikon Systems business unit extends state-of-the-art imaging instruments (SMT platform) to select academic and industry researchers through the Eikon Technology Access Program, enabling study of model systems using Eikon's instruments; an instrument/access-based revenue stream parallel to therapeutic development.

eikontx.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Others
Pricing details1 tier
1No pricing publicly disclosed (pre-revenue clinical-stage biopharma)
ModelOther
Notes

Not applicable - all drug candidates are investigational.

eikontx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Eikon Systems
Description

Business unit that provides academic and industry researchers access to Eikon's proprietary imaging instruments and Single Molecule Tracking (SMT) technology through the Eikon Technology Access Program, enabling the study of protein motion in living cells.

eikontx.com
Core offering1 text field

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that discovers and develops oncology drug candidates using its proprietary Single Molecule Tracking (SMT) platform, which combines Nobel Prize-winning super-resolution microscopy, bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells. Its pipeline includes clinical-stage candidates EIK1001 (TLR7/8 dual agonist), EIK1003 and EIK1004 (PARP1-selective inhibitors), and EIK1005 (WRN helicase inhibitor), with an IND-enabling AR antagonist EIK1006, alongside an Eikon Systems unit that provides external researchers access to its imaging instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • EIK1001 Phase 2 in first-line Stage 4 NSCLC: 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR) across 65 evaluable patients in combination with pembrolizumab and chemotherapy; squamous cohort 72.4% ORR, non-squamous cohort 55.6% ORR.
+5 more records
Product overview1 text field

Eikon Therapeutics is a late-stage clinical biopharmaceutical company built around a unified proprietary platform-plus-pipeline architecture. The foundation is the Single Molecule Tracking (SMT) Platform, a core discovery engine that integrates Nobel Prize-winning super-resolution microscopy (including the Oblique Line Scan/OLS illumination technology), bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells at industrial scale. This platform feeds directly into a portfolio of clinical-stage oncology drug candidates — EIK1001 (TLR7/8 dual agonist in Phase 2 for NSCLC and melanoma), EIK1003 and EIK1004 (PARP1-selective inhibitors in Phase 1, including the CNS-penetrant EIK1004), and EIK1005 (WRN helicase inhibitor in Phase 1) — together with earlier-stage assets such as EIK1006 (androgen receptor antagonist in IND-enabling studies) and undisclosed neuroscience programs. The SMT platform also powers the Eikon Systems business unit, which extends the imaging technology to external academic and industry researchers through the Technology Access Program, creating a discovery engine that drives both internal pipeline advancement and external scientific collaboration.

Product and service6 records
1Single Molecule Tracking (SMT) Platform
CategoryDrug Discovery Platform / Live-Cell Imaging Service
Description

Eikon's proprietary core discovery engine that visualizes and measures the real-time movement of individual proteins in living cells. Captures hundreds of thousands of protein motion events in less than a second and produces high-dimensional datasets describing protein state, localization, diffusion rates, angular movement, processivity, and rate constants. Used internally for drug target identification and SAR optimization, and accessed externally by researchers through the Eikon Systems Technology Access Program.

2EIK1001
CategoryClinical-Stage Oncology Drug Candidate
Description

Investigational systemically administered dual-agonist of Toll-like receptors 7 and 8 (TLR7/8) designed to stimulate both innate and adaptive immune responses and complement PD-(L)1 blockade. In Phase 2/3 development in advanced melanoma (TeLuRide-006) and first-line Stage 4 non-small cell lung cancer (TeLuRide-005, TeLuRide-008) in combination with pembrolizumab with or without chemotherapy. Designed for outpatient systemic administration.

3EIK1003
CategoryClinical-Stage Oncology Drug Candidate
Description

Next-generation, highly-selective PARP1 inhibitor designed to leave PARP2 signaling intact, potentially reducing hematological toxicity associated with first-generation non-selective PARP inhibitors. In Phase 1/2 trial (EIK1003-001) as monotherapy and in combination with hormonal blockade (prostate cancer) or chemotherapy (breast or ovarian cancer).

4EIK1004
CategoryClinical-Stage Oncology Drug Candidate
Description

CNS-penetrant, highly-selective PARP1 inhibitor differentiated by its ability to cross the blood-brain barrier. In Phase 1/2 trial (EIK1004-001) in patients with advanced solid tumors, including those with brain metastases. In-licensed from Impact Therapeutics.

5EIK1005
CategoryClinical-Stage Oncology Drug Candidate
Description

WRN (Werner) helicase inhibitor with demonstrated in vitro activity in MSI-high cancer cells. Internally derived and optimized using Eikon's SMT technology platform. In Phase 1/2 trial in patients with advanced solid tumors including MSI-H or dMMR tumors, both as monotherapy and in combination with pembrolizumab.

6EIK1006
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Clinical trial collaboration and supply agreement: Merck supplies pembrolizumab (Keytruda) for Eikon's TeLuRide-006 Phase 2/3 trial of EIK1001 in advanced melanoma (first patient enrolled May 2025). Eikon is the sponsor of the trial. Merck is also expected to purchase approximately 10% of Eikon's IPO offering shares (Feb 2026). Merck further deepened oncology engagement with Eikon as a key collaborator.

2Impact Therapeutics (Shanghai) Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Collaboration partner for EIK1003 and EIK1004 PARP1-selective inhibitor programs. Impact Therapeutics is responsible for trial oversight in greater China; Eikon leads global development. A $5.0 million milestone payment to Impact Therapeutics was made in Q1 2026 for advancement of EIK1003 into Phase 2 development. Co-developed IND-enabling studies for brain-penetrant PARP1 candidate IMP17307 (now EIK1004).

eikontx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eikon Therapeutics

Clinical-stage Oncology Biopharmaceuticalseikontx.com

Eikon Therapeutics is a clinical-stage biopharmaceutical company that uses proprietary live-cell Single Molecule Tracking microscopy — built on Nobel Prize-winning super-resolution optics — to discover and develop oncology drug candidates including TLR7/8 and PARP1 inhibitors, serving patients with advanced and treatment-resistant cancers.

What Eikon Therapeutics does

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that develops live-cell resolution microscopy and engineering tools for drug discovery. Founded in 2019 in Millbrae, California by Robert Tjian, Luke Lavis, Xavier Darzacq, and Nobel laureate Eric Betzig, the company completed an upsized initial public offering on Nasdaq (ticker: EIKN) on February 5, 2026, raising approximately $381 million in gross proceeds. Eikon applies its proprietary Single Molecule Tracking (SMT) platform — built on Nobel Prize-winning super-resolution microscopy and extended through the proprietary Oblique Line Scan (OLS) illumination technology — to visualize and measure the real-time movement of individual proteins in living cells at industrial scale, generating approximately one petabyte of imaging data per week.

The company's pipeline centers on clinical-stage oncology candidates, including EIK1001, a TLR7/8 dual agonist in Phase 2 development in first-line Stage 4 NSCLC and advanced melanoma in combination with pembrolizumab; EIK1003 and EIK1004, PARP1-selective inhibitors in Phase 1/2 development (EIK1004 is differentiated by CNS penetrance); EIK1005, a WRN helicase inhibitor that entered Phase 1/2 in February 2026 as the first program advanced from internal SMT discovery; and EIK1006, an androgen receptor antagonist in IND-enabling studies. The Eikon Systems business unit, established in 2024, extends SMT imaging instruments to external academic and industry researchers through the Eikon Technology Access Program.

Eikon is pre-revenue and operates a capital-intensive, clinical-development-driven business model with no approved products on market. Revenue mechanics currently consist of (1) capital deployment (over $1.1 billion raised privately plus $381M IPO proceeds) funding registration-enabling Phase 2/3 trials and Phase 1 programs across 28 countries on 5 continents, and (2) early-stage Eikon Systems instrument access. The company reported a FY2025 net loss of $333.6M and Q1 2026 net loss of $83.0M, with cash, cash equivalents, and marketable securities of $596.0 million as of March 31, 2026, expected to fund operations into the second half of 2027. Strategic collaboration with Merck & Co. covers pembrolizumab supply for EIK1001 trials, and Impact Therapeutics handles greater China clinical operations for EIK1003/EIK1004.

Eikon Therapeutics firmographics

Firmographics
Name
Eikon Therapeutics
Legal name
Eikon Therapeutics, Inc.
Website
https://eikontx.com
Company type
Public
Founded year
2019
Operating status
Ipo
Headcount range
251–500 employees
Short description
Eikon Therapeutics is a clinical-stage biopharmaceutical company that uses proprietary live-cell Single Molecule Tracking microscopy — built on Nobel Prize-winning super-resolution optics — to discover and develop oncology drug candidates including TLR7/8 and PARP1 inhibitors, serving patients with advanced and treatment-resistant cancers.
Ownership category
akta.pro rank

Eikon Therapeutics industry classification

Industry
Product category
Clinical-stage Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oncology therapeutics
  • Single molecule imaging
  • Live-cell microscopy
  • Clinical-stage biopharmaceuticals
  • Drug discovery platform

Where Eikon Therapeutics is headquartered

Location

Headquarters

HQ city
Millbrae
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Eikon Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

  1. Pre-revenue clinical-stage biopharmaceutical: Eikon is pre-revenue as of Q1 2026; net loss was $83.0 million in Q1 2026 and $333.6 million for full-year 2025, with no approved products on the market. Future revenue expected from commercialization of oncology drug candidates (EIK1001, EIK1003, EIK1004, EIK1005, EIK1006) once approved.
  2. Eikon Systems / Technology Access Program: Eikon Systems business unit extends state-of-the-art imaging instruments (SMT platform) to select academic and industry researchers through the Eikon Technology Access Program, enabling study of model systems using Eikon's instruments; an instrument/access-based revenue stream parallel to therapeutic development.

Pricing tiers

ModelBillingPrice
Other—No pricing publicly disclosed (pre-revenue clinical-stage biopharma)

Go-to-market motion4 records

Distribution channels2 records

Marketing channels9 records

Eikon Therapeutics product offering

Product offering

Core offering

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that discovers and develops oncology drug candidates using its proprietary Single Molecule Tracking (SMT) platform, which combines Nobel Prize-winning super-resolution microscopy, bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells. Its pipeline includes clinical-stage candidates EIK1001 (TLR7/8 dual agonist), EIK1003 and EIK1004 (PARP1-selective inhibitors), and EIK1005 (WRN helicase inhibitor), with an IND-enabling AR antagonist EIK1006, alongside an Eikon Systems unit that provides external researchers access to its imaging instruments.

Product overview

Eikon Therapeutics is a late-stage clinical biopharmaceutical company built around a unified proprietary platform-plus-pipeline architecture. The foundation is the Single Molecule Tracking (SMT) Platform, a core discovery engine that integrates Nobel Prize-winning super-resolution microscopy (including the Oblique Line Scan/OLS illumination technology), bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells at industrial scale. This platform feeds directly into a portfolio of clinical-stage oncology drug candidates — EIK1001 (TLR7/8 dual agonist in Phase 2 for NSCLC and melanoma), EIK1003 and EIK1004 (PARP1-selective inhibitors in Phase 1, including the CNS-penetrant EIK1004), and EIK1005 (WRN helicase inhibitor in Phase 1) — together with earlier-stage assets such as EIK1006 (androgen receptor antagonist in IND-enabling studies) and undisclosed neuroscience programs. The SMT platform also powers the Eikon Systems business unit, which extends the imaging technology to external academic and industry researchers through the Technology Access Program, creating a discovery engine that drives both internal pipeline advancement and external scientific collaboration.

Differentiator

Problem solved

Functional benefit

Brands

  • Eikon Systems: Business unit that provides academic and industry researchers access to Eikon's proprietary imaging instruments and Single Molecule Tracking (SMT) technology through the Eikon Technology Access Program, enabling the study of protein motion in living cells.

Products and services

  • Single Molecule Tracking (SMT) Platform Eikon's proprietary core discovery engine that visualizes and measures the real-time movement of individual proteins in living cells. Captures hundreds of thousands of protein motion events in less than a second and produces high-dimensional datasets describing protein state, localization, diffusion rates, angular movement, processivity, and rate constants. Used internally for drug target identification and SAR optimization, and accessed externally by researchers through the Eikon Systems Technology Access Program.
  • EIK1001 Investigational systemically administered dual-agonist of Toll-like receptors 7 and 8 (TLR7/8) designed to stimulate both innate and adaptive immune responses and complement PD-(L)1 blockade. In Phase 2/3 development in advanced melanoma (TeLuRide-006) and first-line Stage 4 non-small cell lung cancer (TeLuRide-005, TeLuRide-008) in combination with pembrolizumab with or without chemotherapy. Designed for outpatient systemic administration.
  • EIK1003 Next-generation, highly-selective PARP1 inhibitor designed to leave PARP2 signaling intact, potentially reducing hematological toxicity associated with first-generation non-selective PARP inhibitors. In Phase 1/2 trial (EIK1003-001) as monotherapy and in combination with hormonal blockade (prostate cancer) or chemotherapy (breast or ovarian cancer).
  • EIK1004 CNS-penetrant, highly-selective PARP1 inhibitor differentiated by its ability to cross the blood-brain barrier. In Phase 1/2 trial (EIK1004-001) in patients with advanced solid tumors, including those with brain metastases. In-licensed from Impact Therapeutics.
  • EIK1005 WRN (Werner) helicase inhibitor with demonstrated in vitro activity in MSI-high cancer cells. Internally derived and optimized using Eikon's SMT technology platform. In Phase 1/2 trial in patients with advanced solid tumors including MSI-H or dMMR tumors, both as monotherapy and in combination with pembrolizumab.
  • EIK1006

Quantifiable outcome

  • EIK1001 Phase 2 in first-line Stage 4 NSCLC: 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR) across 65 evaluable patients in combination with pembrolizumab and chemotherapy; squamous cohort 72.4% ORR, non-squamous cohort 55.6% ORR.
  • +5 more outcomes

Companies that use Eikon Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Eikon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Eikon Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Merck & Co. (MSD)flagshipStrategic or Co-development Partner · 1 May 2025Clinical trial collaboration and supply agreement: Merck supplies pembrolizumab (Keytruda) for Eikon's TeLuRide-006 Phase 2/3 trial of EIK1001 in advanced melanoma (first patient enrolled May 2025). Eikon is the sponsor of the trial. Merck is also expected to purchase approximately 10% of Eikon's IPO offering shares (Feb 2026). Merck further deepened oncology engagement with Eikon as a key collaborator.
  • Impact Therapeutics (Shanghai) Inc.coreStrategic or Co-development Partner · 1 June 2023Collaboration partner for EIK1003 and EIK1004 PARP1-selective inhibitor programs. Impact Therapeutics is responsible for trial oversight in greater China; Eikon leads global development. A $5.0 million milestone payment to Impact Therapeutics was made in Q1 2026 for advancement of EIK1003 into Phase 2 development. Co-developed IND-enabling studies for brain-penetrant PARP1 candidate IMP17307 (now EIK1004).

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Eikon Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Eikon Therapeutics social profiles

Digital presence

Eikon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eikon Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Eikon Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Eikon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eikon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eikon Therapeutics

What does Eikon Therapeutics do?

Eikon Therapeutics is a late-stage clinical biopharmaceutical company that discovers and develops oncology drug candidates using its proprietary Single Molecule Tracking (SMT) platform, which combines Nobel Prize-winning super-resolution microscopy, bespoke high-throughput automation, and AI/ML-driven data analytics to visualize and measure the real-time movement of individual proteins in living cells. Its pipeline includes clinical-stage candidates EIK1001 (TLR7/8 dual agonist), EIK1003 and EIK1004 (PARP1-selective inhibitors), and EIK1005 (WRN helicase inhibitor), with an IND-enabling AR antagonist EIK1006, alongside an Eikon Systems unit that provides external researchers access to its imaging instruments.

Is Eikon Therapeutics a public or private company?

Eikon Therapeutics is a public company. It is classified as public and is currently ipo.

When was Eikon Therapeutics founded?

Eikon Therapeutics was founded in 2019. It employs 251 to 500 people.

Where is Eikon Therapeutics based?

Eikon Therapeutics is headquartered in Millbrae, United States, in the North America region.

How does Eikon Therapeutics make money?

Two revenue lines are on record. Pre-revenue clinical-stage biopharmaceutical is the primary driver. The others are eikon Systems / Technology Access Program.

Does Eikon Therapeutics have an API?

No public API is recorded for Eikon Therapeutics.

What industry is Eikon Therapeutics in?

Eikon Therapeutics's product category is Clinical-stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMorgan Stanley maintains Eikon Therapeutics at Overweight, lowers price target to $30 from $32Morgan Stanley maintained Eikon Therapeutics at Overweight and lowered its price target to $30 from $32, a 6.2% decrease. The target implies an upside of 482.5% from the Nov 17 close of $5.15.MarketScreenerEikon Therapeutics, Inc. Announces Clearance To Proceed With First-In-Human Phase 1/2 Study For Novel Androgen Receptor Antagonist EIK1006 In Advanced Metastatic Prostate CancerEikon Therapeutics received FDA clearance to proceed with a Phase 1/2 study of EIK1006 for advanced metastatic prostate cancer. The study will evaluate safety, tolerability, and preliminary efficacy in patients with androgen-pathway-modulation-resistant disease. Dosing is expected to begin in 2027, with preliminary data available in the second half of 2027.Quiver QuantitativeEIKON THERAPEUTICS ($EIKN) Releases Q3 2026 Earnings | EIKN Stock NewsEikon Therapeutics reported Q3 2026 earnings of -$1.59 per share, beating estimates of -$1.73 by $0.14, with revenue of $0. The stock fell 8.4% after market open. Insider trading and hedge fund activity were also disclosed.MarketScreenerEikon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Eikon Therapeutics reported a Q3 net loss of $86.11 million and a nine-month net loss of $257.48 million, both higher than the prior year. Basic and diluted loss per share from continuing operations were $1.59 and $5.43, respectively, compared to $24.24 and $89.06 a year ago.Business & FinancialEikon Therapeutics Reports Third Quarter 2026 Financial Results And Provides Clinical UpdatesEikon Therapeutics reported Q3 2026 results with $461.7 million in cash and a net loss of $86.1 million. The company updated its runway guidance to the first quarter of 2028 and presented clinical data from its oncology programs, including EIK1001 in NSCLC.Investing.comEikon Therapeutics at guggenheim healthcare conference: pipeline gainsEikon Therapeutics presented its oncology pipeline at the Guggenheim Healthcare Innovation Conference, highlighting a 72% overall response rate for EIK1001 combined with KEYTRUDA and chemotherapy in squamous non-small cell lung cancer. The company reported over 600 patients treated with EIK1001 and $531.2 million in cash, with potential for accelerated approval.MarketBeatEikon Therapeutics, Inc. $EIKN Shares Newly Bought by Regents of The University of CaliforniaRegents of the University of California acquired a new stake in Eikon Therapeutics, buying 635,131 shares worth about $5.1 million in Q3. The stake represents 0.1% of the fund's holdings and 1.17% of Eikon's shares. Analysts have a consensus 'Moderate Buy' rating with a price target of $24.67.MarketScreenerEikon Therapeutics, Inc. Presents Initial And Updated Data For EIK1003, EIK1004 And EIK1005 At The 2026 European Society For Medical Oncology CongressEikon Therapeutics presented initial and updated data for EIK1003, EIK1004, and EIK1005 at the 2026 ESMO Congress. EIK1003 monotherapy showed a 14.3% overall response rate in 65 participants, while EIK1003 plus abiraterone and paclitaxel also demonstrated activity. EIK1004 monotherapy had a 12.1% response rate in 68 participants, and EIK1005 data were preliminary.TradingViewEikon Therapeutics Reports ESMO Data Across PARP1 and WRN ProgramsEikon Therapeutics presented ESMO data showing preliminary antitumor activity and manageable safety for its EIK1003, EIK1004, and EIK1005 programs. EIK1003 monotherapy yielded a 14.3% overall response rate, with 31.3% among PARP-inhibitor-naïve participants, while EIK1004 showed a 12.1% response rate. The company expects additional EIK1005 results and combination data in 2027.TradingViewEikon Therapeutics, Inc. (EIKN) Posts PARP1 and WRN Early Clinical Data at ESMOEikon Therapeutics presented early clinical data for its PARP1 inhibitors EIK1003 and EIK1004 and WRN inhibitor EIK1005 at ESMO. EIK1003 showed 14.3% ORR in monotherapy and 26.4% with paclitaxel, while EIK1004 had 12.1% ORR with minimal Grade 3+ hematologic toxicities. EIK1005 showed a partial response in a patient with MSI-H/dMMR biology, with next data expected in 2027.